Clichy
Clichy
Clichy, France130 results · Page 1 of 6
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | Digestive System Diseases, Fibrosis, Hepatic Insufficiency, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute liver failure, chronic liver failure, cirrhosis of liver, liver disorder, liver failure | Recruiting | Not stated | 2026-10-08 | NCT07585890 | |
| A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) | Digestive System Diseases, Infections, RNA Virus Infections, hepatitis, hepatitis D virus infection, liver disorder, viral hepatitis, viral infectious disease | Recruiting | Phase 3 | 2026-10-08 | NCT07200908 | |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-08 | NCT07165028 | |
| Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 3 | 2026-10-07 | NCT03298451 | |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Digestive System Diseases, Fibrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-05 | NCT06419374 | |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Digestive System Diseases, Fibrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-05 | NCT06318169 | |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | Adenoma, Islet Cell, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, adenoma, carcinoid tumor, carcinoma, digestive system neuroendocrine neoplasm, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, neuroendocrine neoplasm, pancreas disorder, pancreatic neoplasm, pancreatic neuroendocrine tumor, primitive neuroectodermal tumor | Active, not recruiting | Phase 3 | 2026-10-05 | NCT05477576 | |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Metabolic Dysfunction Associated Steatohepatitis | Recruiting | Phase 3 | 2026-10-01 | NCT06632457 | |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Digestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder | Recruiting | Phase 3 | 2026-10-01 | NCT06632444 | |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Recruiting | Phase 3 | 2026-10-01 | NCT06016842 | |
| Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures | Carcinoma, Ductal, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, microphthalmia, syndromic 9, neoplasm, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm | Active, not recruiting | Not applicable | 2026-10-01 | NCT05475366 | |
| DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy | Extrapulmonary Neuroendocrine Cancer (epNEC) | Recruiting | Phase 3 | 2026-09-29 | NCT07544654 | |
| Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS | Digestive System Diseases, Intestinal Failure, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, digestive system disorder, disease, intestinal disorder, malabsorption syndrome, metabolic disease, short bowel syndrome, syndromic disease | Recruiting | Phase 3 | 2026-09-29 | NCT07197944 | |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Adenoma, Islet Cell, Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, neuroendocrine neoplasm, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 / Phase 3 | 2026-09-29 | NCT06943755 | |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, biliary tract cancer, biliary tract disorder, gallbladder disorder, gallbladder neoplasm, neoplasm | Recruiting | Phase 3 | 2026-09-28 | NCT07221253 | |
| A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-28 | NCT04033445 | |
| An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | Digestive System Diseases, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, colitis, colonic disorder, digestive system disorder, gastroenteritis, immune system disorder, immunoproliferative disorder, inflammatory bowel disease, intestinal disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, ulcerative colitis | Active, not recruiting | Not stated | 2026-09-25 | NCT02808780 | |
| Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions | Blood-Borne Infections, Chronic Disease, DNA Virus Infections, Digestive System Diseases, Disease Attributes, Hepadnaviridae infectious disease, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic hepatitis B virus infection, hepatitis, hepatitis B virus infection, infectious disease, liver disorder, viral hepatitis, viral infectious disease | Recruiting | Phase 2 | 2026-09-24 | NCT07654283 | |
| A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease | Immunoglobulin G4-Related Disease, autoimmune disease, immune system disorder | Recruiting | Phase 3 | 2026-09-23 | NCT07190196 | |
| A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Simpson-Golabi-Behmel syndrome, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-16 | NCT06427941 | |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoid syndrome, carcinoid tumor, carcinoma, cecum neuroendocrine tumor G1, enterochromaffin cell serotonin-producing pancreatic neuroendocrine tumor, epithelial neoplasm, ileal neuroendocrine tumor G1, intestinal neuroendocrine tumor G1, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, serotonin syndrome | Recruiting | Phase 3 | 2026-09-15 | NCT07087054 | |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, biliary tract cancer, biliary tract disorder, carcinoma, cholangiocarcinoma, epithelial neoplasm, gallbladder disorder, gallbladder neoplasm, neoplasm | Recruiting | Phase 3 | 2026-09-14 | NCT06282575 | |
| Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Site, liver disorder, neoplasm | Active, not recruiting | Phase 3 | 2026-09-14 | NCT05883644 | |
| A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | Blood-Borne Infections, Chronic Disease, DNA Virus Infections, Digestive System Diseases, Disease Attributes, Hepadnaviridae infectious disease, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic hepatitis B virus infection, hepatitis, hepatitis B virus infection, infectious disease, liver disorder, viral hepatitis, viral infectious disease | Active, not recruiting | Phase 2 | 2026-09-11 | NCT06963710 | |
| Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, digestive system neuroendocrine neoplasm, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-09-11 | NCT06784752 |